Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles (EVs): Technologies & Biological Investigations

Abdolmohamad Rostami's Biography



Abdolmohamad Rostami, Nicholas Maiale Distinguished Professor and Chair of the Department of Neurology, Thomas Jefferson University

Abdolmohamad Rostami, MD, PhD is Nicholas Maiale distinguished professor and Chair of the Department of Neurology and director of multiple sclerosis/neuroimmunology research laboratory at Thomas Jefferson University in Philadelphia. Formerly a tenured professor of neurology and medicine, chief of multiple sclerosis and neuroimmunology division and director of Autoimmunity Center of Excellence at the University of Pennsylvania (Penn). Dr. Rostami received an MD with distinction from Shiraz University in Iran and a PhD in molecular biology from Penn. He completed his residency training followed by a fellowship in clinical multiple sclerosis and basic neuroimmunology at Penn. He then joined the faculty at the department of neurology at Penn and rose to full professor of neurology and medicine.

Dr. Rostami’s research interest is in the immunopathogenesis of multiple sclerosis and finding better therapies for this disease. He uses experimental autoimmune encephalomyelitis as a model for MS. His lab has focused on the role Th17 cells and GM-CSF in EAE/MS pathogenesis. He also studies antigen specific tolerance as a mechanism to find therapies to remove the autoreactive T cells without systemic immunosuppression in autoimmune diseases. His lab has been continuously funded by the NIH since receiving his FIRST Award as a new faculty at Penn and serves on various NIH committees.

Dr. Rostami has published over 200 original papers and many review articles and book chapters. In addition to the clinical residency training, he has trained more the 60 pre and postdoctoral students and fellows who now have their own laboratories and hold leadership positions in the US and around the world. He is on the editorial board of many scientific journals and is the elected member of national and international organizations and serves on their committees.

Abdolmohamad Rostami Image

Oligodendrocyte-derived Extracellular Vesicles as Antigen-specific Therapy in Experimental Models of Multiple Sclerosis

Wednesday, 15 December 2021 at 13:30

Add to Calendar ▼2021-12-15 13:30:002021-12-15 14:30:00Europe/LondonOligodendrocyte-derived Extracellular Vesicles as Antigen-specific Therapy in Experimental Models of Multiple SclerosisExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Autoimmune diseases such as multiple sclerosis (MS) develop because of failed peripheral immune tolerance for a specific self-antigen (Ag). Numerous approaches for Ag-specific suppression of autoimmune neuro-inflammation have been proven effective in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. One such approach is intravenous tolerance induction by injecting a myelin Ag used for triggering EAE. However, the translation of this and similar experimental strategies into therapy for MS has been hampered by uncertainty regarding relevant myelin Ags in MS patients. To address this issue, we developed a therapeutic strategy that relies on oligodendrocyte (Ol) derived extracellular vesicles (Ol-EVs), which naturally contain multiple myelin Ags. Intravenous Ol-EV injection reduced disease pathophysiology in a myelin Ag–dependent manner, both prophylactically and therapeutically, in several EAE models. The treatment was safe and restored immune tolerance by inducing immunosuppressive monocytes and apoptosis of autoreactive CD4+ T cells. Furthermore, we showed that human Ols also released EVs containing most relevant myelin Ags, providing a basis for their use in MS therapy. These findings introduce an approach for suppressing central nervous system (CNS) autoimmunity in a myelin Ag–specific manner, without the need to identify the target Ag and no systemic immunosuppression.


Add to Calendar ▼2021-12-13 00:00:002021-12-15 00:00:00Europe/LondonExtracellular Vesicles (EVs): Technologies and Biological InvestigationsExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com